NCT03801889

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Multicenter, Open-label, 52 Week, Dose-escalation Study of SP 420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Abfero Pharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.

Conditions

• Iron Overload
• Beta-Thalassemia

Interventions

Type	Name	Description
DRUG	SP-420	Self-administered by mouth

Timeline

• Start date: 2020-08-01
• Primary completion: 2022-09-01
• Completion: 2023-01-01
• First posted: 2019-01-14
• Last updated: 2020-10-05

Locations

4 sites across 4 countries: Canada, Lebanon, Thailand, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study